The abstract is read at the publisher; the summary is JClub's.
Intramuscular SARS-CoV-2 priming in UK adults aged 50+ did not induce de novo nasal anti-spike IgA after one or two doses across 28- or 84-day schedules.
- Why it matters: Intramuscular vaccines may not generate local nasal immunity, and nasal IgA could be confounded by asymptomatic community SARS-CoV-2 exposure.
- What they did: In the Com-COV substudy, 101 infection-naive, unvaccinated adults collected nasal lining fluid via nasosorption strips; anti-spike and anti-nucleocapsid IgG/IgA were measured in serum and nasal samples by electrochemiluminescence immunoassay after ChAd/BNT or BNT/BNT at 28- or 84-day intervals.
- The result: Nasal anti-spike IgA increased from baseline for ChAd-BNT (612·8 AU/mL; fold rise 2·78) and BNT-BNT (906·4 AU/mL; fold rise 3·11), but mucosal IgA trajectories did not track serum anti-spike IgG (r=0·13, p=0·013) and instead correlated with mucosal anti-nucleocapsid IgA (r=0·78, p=5×10−77).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.